CSL Limited · ASX:CSL
CSL — H1 FY2001 Earnings Presentation
17 slides from CSL's earnings presentation, February 2001
Slide 1: CSL Limited
CSL LIMITED AUSTRALIA’S BIO-PHARMACEUTICAL COMPANY
Slide 2: 2000/01 Healthy Progress
2000/01 Healthy Progress • Revenue growth of 60% • Quality margins maintained – EBITDA of $78.5m increase of 88% – NPAT pre amort. $37.3m increase of 100% – EPS on NPAT pre amort. 24.9c (diluted 24.5c) • International sales now at 52% • Dividend - 9 cents fully franked
Slide 3: Sales by Business Unit December 2000
Sales by Business Unit December 2000 $335m Animal Health 10% Biosciences 15% Pharmaceutical 20% Bioplasma 55%
Slide 4: Total Revenues
Total Revenues $400 343 $350 $300 214 196 $250 Million $200 $150 $100 $50 $0 1998 1999 2000 Half year ending 31 December
Slide 5: EBITDA
EBITDA $90 78.5 $80 $70 $60 40.5 41.9 Million $50 $40 $30 $20 $10 $0 1998 1999 2000 Half year ending 31 December
Slide 6: ZLB - Successful Integration
ZLB - Successful Integration • Strong sales performance • Margins in line with expectations • Cultural alignment • US sales and marketing office established • Integration between sites creates innovation opportunities
Slide 7: ZLB Acquisition Impact Balance Sheet/Financial Leverage
ZLB Acquisition Impact Balance Sheet/Financial Leverage • Goodwill – Amortised over 20 years – Tax deductable over 8 years in Switzerland – Canton tax relief • Vendor note • Prudent Gearing
Slide 8: Bioplasma (Domestic)
Bioplasma (Domestic) • Strong sales growth of 10% • Export sales growth of 12% • Plasma intake slows – donor deferral
Slide 9: Pharmaceutical
Pharmaceutical • Fluvax™ potential international commercialisation – demand continues to increase – capital program to expand capacity • Flu B strain low yielding • FluMist™ filing for registration April 2001
Slide 10: Animal Health/JRH Biosciences
Animal Health/JRH Biosciences • Animal Health – Rural sales drive growth – Niche products in US show promise • JRH Biosciences – Sales growth continues at 15% – Demand for media remains strong
Slide 11: Refocussed R&D Strategy
Refocussed R&D Strategy
Slide 12: Convergence in Immunotherapy
Convergence in Immunotherapy Enhancement Asthma Allergy ACTIVE PASSIVE Cancer MS Genital warts Psoriasis Peptic ulcers Diabetes Hepatitis R. Arthritis Suppression Mistakes / Mimicry
Slide 13: ZLB Convergence Projects
ZLB Convergence Projects • IVIG – ZLB enhancements – Broadmeadows + Berne expertise • Anti-D – Rhophylac HDN and ITP clinicals – Recombinant MAb development • Reconstituted HDL – plasma proof-of-principle to recombinant product
Slide 14: HPV Vaccine Project
HPV Vaccine Project Merck and Co. All 4 types currently undergoing human testing • Annual incidence of Cervical Good immune Cancer: 471,000 new cases response shown for all proteins in quadrivalent formulation • Yearly cost of management in US: Evidence that Type 16 $6 billion protein prevents infec
Slide 15: ISCOM Adjuvant Technology
ISCOM™ Adjuvant Technology • Cancer – Cervical Dysplasia – Ludwig ESO-1 • Chronic I.D. – Chiron HCV • Enabling the promise of recombinant- based protein therapeutics
Slide 16: CSL is committed to creating shareholder value
CSL is committed to creating shareholder value • Financial performance • Growth and international market access, particularly USA • Leverage innovation and technological advantage
Slide 17: Group Results December
Group Results December 2000 $m 1999 $m Sales 335.4 209.5 Other Revenue 8.1 4.6 Total Revenue 343.5 214.1 Depreciation 22.9 15.5 Net Interest Expense 6.0 (1.0) Tax Expense 10.8 8.9 Profit after tax before amortisation 37.3 18.6 Amortisation 10.0 0 Net Profit 27.3 18.6 Interim Dividend (cents) 9.0 8.0